➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
Colorcon
McKinsey
Moodys

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXYBUTYNIN CHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Oxybutynin Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00269724 ↗ A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence Completed Alza Corporation, DE, USA Phase 3 1997-03-01 The purpose of this study is to is to evaluate the safety and efficacy of OROS® oxybutynin chloride in patients being treated for urge urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
NCT00269750 ↗ A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. Completed Alza Corporation, DE, USA Phase 3 1996-07-01 The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
NCT00293839 ↗ Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder Completed Alza Corporation, DE, USA Phase 3 1969-12-31 The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxybutynin Chloride

Condition Name

Condition Name for Oxybutynin Chloride
Intervention Trials
Healthy 7
Urinary Incontinence 2
Neurogenic Detrusor Overactivity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxybutynin Chloride
Intervention Trials
Urinary Bladder, Overactive 4
Urinary Incontinence 3
Hot Flashes 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxybutynin Chloride

Trials by Country

Trials by Country for Oxybutynin Chloride
Location Trials
United States 27
Canada 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxybutynin Chloride
Location Trials
West Virginia 3
North Dakota 3
North Carolina 2
Michigan 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxybutynin Chloride

Clinical Trial Phase

Clinical Trial Phase for Oxybutynin Chloride
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxybutynin Chloride
Clinical Trial Phase Trials
Completed 16
Not yet recruiting 3
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxybutynin Chloride

Sponsor Name

Sponsor Name for Oxybutynin Chloride
Sponsor Trials
Mylan Pharmaceuticals 6
Watson Pharmaceuticals 3
Alza Corporation, DE, USA 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxybutynin Chloride
Sponsor Trials
Industry 17
Other 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
Harvard Business School
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.